Evaluation of metabolic alterations in patient plasma associated with disease aggressiveness in prostate cancer
(English)Manuscript (preprint) (Other academic)
GC-MS was used for the study of plasma metabolite profiles in prostate cancer patients. Multivariate analysis of the acquired data revealed metabolites and metabolite patterns associated with prostate cancer disease progression from benign disease to distant metastases. Moreover, by evaluation of plasma metabolite patterns before and after radical prostatectomy differences associated with biochemical relapse was detected. Specifically we found two unidentified plasma metabolites which showed decreased plasma levels with increased disease progression and, furthermore, increased plasma levels post compared to pre surgery in patients who later experienced biochemical relapse. We hypothesize that those metabolites are consumed by aggressive tumors more than by indolent tumors. Identification of those metabolites are hence crucial, and under-way, in order to enable biological interpretation of the results. We further hypothesized that any tumor-derived metabolite secreted into plasma would show increased concentrations with increased PCa risk. Notably we did not detect any such metabolite, but only a few metabolites which showed increased plasma concentrations in patients with metastases compared to patients with benign disease and low risk PCa. In addition, verification of metabolite markers for metastatic disease detected previously by us and others was made, and included decreased plasma levels of stearic acid and increased levels of pseudouridine with metastatic disease.
Other Medical Sciences not elsewhere specified
IdentifiersURN: urn:nbn:se:umu:diva-50972OAI: oai:DiVA.org:umu-50972DiVA: diva2:471649